Amgen Appoints Howard Chang as Senior Vice President of Research and Chief Scientific Officer

Appointment:
Howard Chang, M.D., Ph.D., will join Amgen as Senior Vice President of Research and Chief Scientific Officer, effective December 16, 2024[1][4].

Responsibilities:
Chang will lead all research priorities within Amgen's therapeutic areas, including rare diseases, oncology, inflammation, and cardiometabolic diseases. He will also oversee operations in key research hubs globally[1].

Background:
Chang is a renowned physician-scientist with expertise in human genetics, gene control, cancer biology, and stem cell biology. He is currently the Virginia and D. K. Ludwig Professor of Cancer Genomics and of Genetics at Stanford University School of Medicine and a Howard Hughes Medical Institute Investigator[2][4].

Awards and Recognition:
Chang has received several prestigious awards, including the 2018 NAS Award in Molecular Biology, the 2024 King Faisal Prize in Biology, and the 2024 Albany Medical Center Prize[2].

Succession:
Chang succeeds Ray Deshaies, Ph.D., former Senior Vice President of Research, whose departure was announced earlier this year[1].